Sickle cell disease may up risk for poor COVID-19 outcomes

Sickle cell disease may up risk for poor COVID-19 outcomes

(HealthDay)—Sickle cell disease is associated with a fourfold increased risk for COVID-19-related hospitalization and a more than twofold increased risk for COVID-19-related death, according to a research letter published online July 20 in the Annals of Internal Medicine.

Ashley Kieran Clift, M.B.B.S., from the University of Oxford in the United Kingdom, and colleagues assessed the risk for COVID-19-related hospitalization (Jan. 24, 2020, to Sept. 30, 2020) and death (to Jan. 18, 2021) in children and adults with sickle cell disorders. The QResearch database was used to identify patients of 1,317 with individual-level linkage to severe acute respiratory syndrome coronavirus 2 test results from Public Health England, hospital admissions data, and the national death register.

The researchers found that sickle cell disease was associated with increased risks for COVID-19-related hospitalization (hazard ratio [HR], 4.11) and death (HR, 2.55). Adults with accounted for 0.79 percent of hospitalizations and 0.20 percent of deaths, while they made up 0.04 percent of the cohort. Individuals with also had a higher risk for COVID-19-related hospitalization (HR, 1.38) and death (HR, 1.51).

"Several aspects of sickle cell phenotypes overlap with the pathophysiology of severe COVID-19, which could be relevant mechanisms worthy of further study, as should the directionality of infection and sickle crisis," the authors write.


Explore further

Study identifies risk factors for severe COVID-19 in individuals with sickle cell disease

More information: Abstract/Full Text
Journal information: Annals of Internal Medicine

Copyright © 2021 HealthDay. All rights reserved.

Citation: Sickle cell disease may up risk for poor COVID-19 outcomes (2021, July 29) retrieved 16 September 2021 from https://medicalxpress.com/news/2021-07-sickle-cell-disease-poor-covid-.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
35 shares

Feedback to editors